Susquehanna International Group’s Neuropace NPCE Stock Holding History
Bought
Maintained
Sold
Other funds holding NPCE
PCH
SCM
FLAM
O
DCM
VCM
AC
Susquehanna International Group's NPCE Position: Q1 2026 in Review
Susquehanna International Group increased its Neuropace (NPCE) stake by 149% in Q1 2026, buying an estimated $226K and bringing the position to 25,180 shares worth $331K. The position accounts for ﹤0.01% of the portfolio, ranked #10656.
Susquehanna International Group first reported a position in NPCE in Q1 2023 and has held it in 8 quarters since. The position peaked at $2.69M in Q1 2024. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.
- Susquehanna International Group held 25,180 shares of Neuropace worth $331K as of Q1 2026.
- Susquehanna International Group bought 15,059 Neuropace shares in Q1 2026, an estimated $226K.
- Neuropace made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10656 holding.
- Susquehanna International Group first reported a position in Neuropace in Q1 2023 and has held it in 8 quarters since.
- Susquehanna International Group's Neuropace position peaked at $2.69M in Q1 2024.
- 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.